15.07.2014 Views

Eisertech Achieves FDA Clearance for New Spinal ... - Solvay Plastics

Eisertech Achieves FDA Clearance for New Spinal ... - Solvay Plastics

Eisertech Achieves FDA Clearance for New Spinal ... - Solvay Plastics

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

For Immediate Release<br />

<strong>Eisertech</strong> <strong>Achieves</strong> <strong>FDA</strong> <strong>Clearance</strong> <strong>for</strong> <strong>New</strong><br />

<strong>Spinal</strong> Implants Made of <strong>Solvay</strong>’s Zeniva ® PEEK<br />

Thermoplastic Biomaterial Delivers High Per<strong>for</strong>mance<br />

in Cervical and Lumbar Cages<br />

ALPHARETTA, Ga., May 28, 2012 – <strong>Eisertech</strong> LLC, a San Diego, Calif.-based<br />

designer and manufacturer of cost-effective spinal implants, has received 510(k) clearance<br />

from the U.S. Food & Drug Administration (<strong>FDA</strong>) <strong>for</strong> its new cervical cage and lumbar<br />

cage implants made of Zeniva ® polyetheretherketone (PEEK) rods from <strong>Solvay</strong> Specialty<br />

Polymers USA, LLC. Zeniva ® PEEK – part of <strong>Solvay</strong>’s line of Solviva ® Biomaterials – has<br />

a modulus very close to that of bone plus excellent toughness and fatigue resistance. The<br />

<strong>FDA</strong> clearance was based in part on <strong>Solvay</strong>’s well-developed master access file <strong>for</strong> Zeniva ®<br />

PEEK.<br />

The cage systems, made from various sizes of Zeniva ® PEEK rods, are hollow so<br />

that bone can grow through the device, fusing the adjacent bony surfaces of the vertebrae.<br />

“Zeniva ® PEEK delivers the high-per<strong>for</strong>mance properties that are necessary <strong>for</strong> a highprecision<br />

implant used in cervical spine fusion surgery,” said Lukas Eisermann, president of<br />

<strong>Eisertech</strong>.<br />

Zeniva ® PEEK offers numerous advantages over metals such as titanium <strong>for</strong> these<br />

intervertebral implantable devices. The material offers many important benefits including<br />

biocompatibility, chemical inertness, and a modulus of elasticity that is close to that of<br />

<strong>Solvay</strong> Specialty Polymers USA, LLC<br />

4500 McGinnis Ferry Road, Alpharetta, Georgia 30005-3914<br />

+1.800.621.4557 (US only) +1.770.772.8760<br />

www.solvayspecialtypolymers.com


<strong>Solvay</strong> Specialty Polymers – <strong>Eisertech</strong> <strong>Achieves</strong> <strong>FDA</strong> <strong>Clearance</strong> <strong>for</strong> <strong>Spinal</strong> Implants Made of Zeniva ® PEEK<br />

Page 2<br />

bone. Based on biocompatibility testing, Zeniva ® PEEK demonstrates no evidence of<br />

cytotoxicity, sensitization, irritation, or acute systemic toxicity. It also boasts high strength<br />

and stiffness and has radiolucent properties which permit x-ray procedures. <strong>Eisertech</strong> buys<br />

Zeniva ® PEEK rod stock directly from <strong>Solvay</strong> and machines and designs a full range of<br />

sizes and configurations.<br />

“We’re excited about the commercial success of Zeniva ® PEEK in the spinal fusion<br />

market,” said Shawn Shorrock, global healthcare market manager <strong>for</strong> <strong>Solvay</strong> Specialty<br />

Polymers. “The ongoing acceptance of Zeniva ® PEEK has validated our approach to the<br />

spinal market and we’re encouraged by the momentum we’ve generated.”<br />

<strong>Eisertech</strong>’s business model is focused on lowering the cost of spinal implants.<br />

Eisermann says the company’s products can be adopted by surgeons without having to<br />

attend a specialty training course, and can be serviced and re-ordered by hospital or surgery<br />

center staff via an online store without assistance from an on-site company representative.<br />

“This arrangement allows us to significantly streamline our business processes and<br />

infrastructure significantly relative to traditional full-service implant manufacturing<br />

companies,” said Eisermann. “That streamlining shows up as savings which we pass on to<br />

our customers.”<br />

Zeniva ® PEEK and the entire line of thermoplastic Solviva ® Biomaterials are<br />

manufactured in compliance with the relevant aspects of ISO 13485 and under the relevant<br />

aspects of current Good Manufacturing Practices. <strong>Solvay</strong>’s biomaterial manufacturing<br />

processes are carefully validated and enhanced controls provide product traceability. In<br />

addition, all materials are tested in an accredited lab that is ISO 17025 compliant.<br />

<strong>Solvay</strong> is currently in active product trials with several major medical device<br />

manufacturers using Zeniva ® PEEK and other Solviva ® Biomaterials.


<strong>Solvay</strong> Specialty Polymers – <strong>Eisertech</strong> <strong>Achieves</strong> <strong>FDA</strong> <strong>Clearance</strong> <strong>for</strong> <strong>Spinal</strong> Implants Made of Zeniva ® PEEK<br />

Page 3<br />

In addition to Zeniva ® PEEK, <strong>Solvay</strong>’s Solviva Biomaterials line includes Proniva ®<br />

self-rein<strong>for</strong>ced polyphenylene (SRP), one of the world’s stiffest and strongest unrein<strong>for</strong>ced<br />

thermoplastics that offers exceptional hardness and biocompatibility; Veriva ®<br />

polyphenylsulfone (PPSU), which provides unsurpassed toughness combined with<br />

transparency and excellent biocompatibility; and Eviva ® polysulfone (PSU), which offers<br />

practical toughness in a strong, transparent polymer. These sterilizable products are<br />

available in injection molding and extrusion grades as well as rods and plates <strong>for</strong> machined<br />

components.<br />

About <strong>Eisertech</strong><br />

<strong>Eisertech</strong> LLC, based in San Diego, Calif., is a supplier of spinal implants made of Zeniva ®<br />

polyetheretherketone (PEEK) rod stock from <strong>Solvay</strong> Specialty Polymers USA, LLC. The<br />

company was founded in 2010 by Lukas Eisermann who has a long track record of product<br />

development within the spinal surgery field. He is an active participant in the creation of<br />

intellectual property and is a named inventor on many U.S. and international patents.<br />

Eisermann has assisted in drafting ASTM standards <strong>for</strong> testing artificial disc devices, and is<br />

a co-author of several book chapters, journal articles, and conference proceedings. He has<br />

been a best paper nominee at major meetings, including the European Spine Society,<br />

IMAST, and NASS.<br />

<strong>Eisertech</strong> products are provided <strong>for</strong> direct sale to healthcare facilities and are delivered via<br />

common commercial carriers. The company offers a high-value proposition <strong>for</strong> those<br />

customers that don’t require on-site service representation. For more in<strong>for</strong>mation, visit<br />

www.eisertech.com.<br />

About <strong>Solvay</strong> Specialty Polymers<br />

<strong>Solvay</strong> Specialty Polymers is a leading global supplier of high-per<strong>for</strong>mance thermoplastics <strong>for</strong><br />

implantable and non-implantable medical devices. The company has expanded its focus on the<br />

healthcare industry to meet the growing needs of its global customers. Last year, <strong>Solvay</strong><br />

announced a new organizational structure and a 50% increase in staffing <strong>for</strong> sales, marketing, and<br />

technology functions in the U.S. and Europe. Plans <strong>for</strong> further expansion in Asia-Pacific are also<br />

underway. <strong>Solvay</strong> is building on its 20-year history as a key material supplier in the healthcare<br />

field, devoting considerable new resources to help customers be more efficient and cut costs.<br />

Metal-to-plastic replacement remains a key focus <strong>for</strong> manufacturers, but increased cost pressures<br />

pose a new challenge as the market continues to grow at a double-digit pace. <strong>Solvay</strong> also<br />

continues to devote considerable research and development activities to polymer technology and<br />

commercialization of new and unique material options <strong>for</strong> medical OEMs and processors.<br />

<strong>Solvay</strong> Specialty Polymers manufactures more products with more per<strong>for</strong>mance than any<br />

other polymer company in the world. The company supplies over 1500 products across 33<br />

brands of high-per<strong>for</strong>mance polymers – fluoropolymers, fluoroelastomers, fluorinated<br />

fluids, semi-aromatic polyamides, sulfone polymers, aromatic ultra polymers, high-barrier


<strong>Solvay</strong> Specialty Polymers – <strong>Eisertech</strong> <strong>Achieves</strong> <strong>FDA</strong> <strong>Clearance</strong> <strong>for</strong> <strong>Spinal</strong> Implants Made of Zeniva ® PEEK<br />

Page 4<br />

polymers and cross-linked high-per<strong>for</strong>mance compounds – <strong>for</strong> use in Aerospace,<br />

Alternative Energy, Automotive, Healthcare, Membranes, Oil & Gas, Packaging, Plumbing,<br />

Semiconductors, Wire & Cable, and other markets. Learn more at<br />

www.solvayspecialtypolymers.com.<br />

<strong>Solvay</strong> is an international chemical Group committed to sustainable development with a<br />

clear focus on innovation and operational excellence. Its recent acquisition of specialty<br />

chemicals company Rhodia created a much larger player which is realizing over 90% of its<br />

sales in markets where it is among the top 3 global leaders. <strong>Solvay</strong> offers a broad range of<br />

products that contribute to improving quality of life and its customers' per<strong>for</strong>mance in<br />

markets such as consumer goods, construction, automotive, energy, water and environment,<br />

and electronics. The Group is headquartered in Brussels and its companies employ about<br />

29,000 people in 55 countries and generated EUR 12.7 billion in net sales in 2011 (pro<br />

<strong>for</strong>ma). <strong>Solvay</strong> SA (<strong>Solvay</strong> SA (SOLB.BE) is listed on NYSE Euronext in Brussels and<br />

Paris (Bloomberg: SOLB.BB - Reuters: SOLBt.BR).<br />

# # #<br />

Press Contact:<br />

Joseph Grande<br />

413.684.246

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!